Acute and rapid degradation of endogenous proteins by Trim-Away
- PMID: 30250286
- DOI: 10.1038/s41596-018-0028-3
Acute and rapid degradation of endogenous proteins by Trim-Away
Erratum in
-
Publisher Correction: Acute and rapid degradation of endogenous proteins by Trim-Away.Nat Protoc. 2019 Aug;14(8):2596. doi: 10.1038/s41596-018-0092-8. Nat Protoc. 2019. PMID: 30504914
Abstract
Protein depletion is a key approach to understanding the functions of a protein in a biological system. We recently developed the Trim-Away approach in order to rapidly degrade endogenous proteins without prior modification. Trim-Away is based on the ubiquitin ligase and Fc receptor TRIM21, which recognizes antibody-bound proteins and targets them for degradation by the proteasome. In a typical Trim-Away experiment, protein degradation is achieved in three steps: first, introduction of an antibody against the target protein; second, recruitment of endogenous or exogenous/overexpressed TRIM21 to the antibody-bound target protein; and third, proteasome-mediated degradation of the target protein, antibody and TRIM21 complex. Protein degradation by Trim-Away is acute and rapid, with half-lives of ~10-20 min. The major advantages of Trim-Away over other protein degradation methods are that it can be applied to any endogenous protein without prior modification; that it uses conventional antibodies that are widely available; and that it can be applied to a wide range of cell types, including nondividing primary human cells, for which other loss-of-function assays are challenging. In this protocol, we describe the detailed procedures for antibody preparation and delivery in mouse oocytes and cultured cells via microinjection and electroporation. In addition, we provide recommendations for antibody selection and validation, and for the generation of TRIM21-overexpressing cell lines for cases in which endogenous TRIM21 is limited. A typical Trim-Away experiment takes just a few hours.
Similar articles
-
TRIM21-dependent target protein ubiquitination mediates cell-free Trim-Away.Cell Rep. 2023 Feb 28;42(2):112125. doi: 10.1016/j.celrep.2023.112125. Epub 2023 Feb 18. Cell Rep. 2023. PMID: 36807144 Free PMC article.
-
Generation and Characterization of a TRIM21 Overexpressing Mouse Line.Genesis. 2024 Oct;62(5):e23616. doi: 10.1002/dvg.23616. Genesis. 2024. PMID: 39487578 Free PMC article.
-
Target-induced clustering activates Trim-Away of pathogens and proteins.Nat Struct Mol Biol. 2021 Mar;28(3):278-289. doi: 10.1038/s41594-021-00560-2. Epub 2021 Feb 25. Nat Struct Mol Biol. 2021. PMID: 33633400 Free PMC article.
-
The molecular mechanisms that drive intracellular neutralization by the antibody-receptor and RING E3 ligase TRIM21.Semin Cell Dev Biol. 2022 Jun;126:99-107. doi: 10.1016/j.semcdb.2021.11.005. Epub 2021 Nov 22. Semin Cell Dev Biol. 2022. PMID: 34823983 Review.
-
Targeted protein degradation using intracellular antibodies and its application to neurodegenerative disease.Semin Cell Dev Biol. 2022 Jun;126:138-149. doi: 10.1016/j.semcdb.2021.09.012. Epub 2021 Oct 13. Semin Cell Dev Biol. 2022. PMID: 34654628 Review.
Cited by
-
Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions.Bioconjug Chem. 2024 Aug 21;35(8):1089-1115. doi: 10.1021/acs.bioconjchem.4c00253. Epub 2024 Jul 11. Bioconjug Chem. 2024. PMID: 38990186 Free PMC article. Review.
-
Recent advancements in targeted protein knockdown technologies-emerging paradigms for targeted therapy.Explor Target Antitumor Ther. 2023;4(6):1227-1248. doi: 10.37349/etat.2023.00194. Epub 2023 Dec 26. Explor Target Antitumor Ther. 2023. PMID: 38213543 Free PMC article. Review.
-
Prey for the Proteasome: Targeted Protein Degradation-A Medicinal Chemist's Perspective.Angew Chem Int Ed Engl. 2020 Sep 1;59(36):15448-15466. doi: 10.1002/anie.202004310. Epub 2020 Jul 30. Angew Chem Int Ed Engl. 2020. PMID: 32428344 Free PMC article. Review.
-
The therapeutic potential of GLP-1 receptor biased agonism.Br J Pharmacol. 2022 Feb;179(4):492-510. doi: 10.1111/bph.15497. Epub 2021 May 20. Br J Pharmacol. 2022. PMID: 33880754 Free PMC article. Review.
-
Extracellular targeted protein degradation: an emerging modality for drug discovery.Nat Rev Drug Discov. 2024 Feb;23(2):126-140. doi: 10.1038/s41573-023-00833-z. Epub 2023 Dec 7. Nat Rev Drug Discov. 2024. PMID: 38062152 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials